NS Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

Continue Learn More X

Home » News » Company News » QIAGEN acquires remaining stake in NeuMoDx Molecular for $248m » conclusion-of-the-contract-3100579_640

QIAGEN acquires remaining stake in NeuMoDx Molecular for $248m

NS Medical Devices is using cookies

QIAGEN fully acquires NeuMoDx Molecular. (Credit: Capri23auto from Pixabay.)

Related Article

Biggest players in the global wound care market

RECOMMENDED COMPANIES

MOST READ

Xstim secures FDA approval for spine fusion stimulator

BostonGene, Saga University partner to discover biomarkers for NSCLC

Babson expands BetterWay blood testing ecosystem with Babson Handwarmer

Ypsomed, ten23 partner on commercialisation of YpsoDose patch injector

Labcorp rolls out new blood-based test to early detect neurodegenerative diseases

Recommended Whitepaper